Does Information about IDUs' Injecting Networks Predict Exposure to the Hepatitis C Virus?

Background and Aims: Many previous studies have used cross-sectional approaches to measure associations between injecting drug users' (IDUs') characteristics and hepatitis C virus (HCV) status, and identified independent predictors of antibody to HCV (anti-HCV) positivity including duration of injecting, needle-sharing history and prior imprisonment. Although HCV transmission between IDUs occurs primarily through blood transfer during close physical interactions, the contribution of social network data to prediction of HCV status has not been previously assessed. Methods: 215 injecting drug users and their injecting network members were recruited in Melbourne, Australia between July 2005 and August 2006. Logistic regression was used to analyze behavioral and social network data for predictors of HCV exposure. Results: IDUs' HCV exposure status was independently associated with the age of first injection of their injecting network members (adjusted OR=2.82, P=0.019) and the HCV exposure status of those network members (adjusted OR = 6.17, P<0.001), in addition to several 'traditional' behavioral and lifetime variables. Conclusions: Patterns of exposure to the hepatitis C virus are influenced by the characteristics of members of IDUs' social networks. HCV RNA and/or antibody testing are an important part of any HCV prevention strategy for IDUs; increased availability of testing and sharing HCV status information within social networks would enable more IDUs to

[1]  A. Moss,et al.  Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco , 2001, Hepatology.

[2]  B. Smyth,et al.  Bloodborne viral infection in Irish injecting drug users. , 1998, Addiction.

[3]  J. Montaner,et al.  Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility. , 2005, Public health.

[4]  Samuel R. Friedman,et al.  Social networks, risk-potential networks, health, and disease , 2001, Journal of Urban Health.

[5]  G. Boiteau,et al.  J. Virol. Methods , 1996, Journal of Virological Methods.

[6]  B. Jalaludin,et al.  Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south‐western Sydney, Australia , 2004, Journal of gastroenterology and hepatology.

[7]  A. Rodger,et al.  Assessment of Long‐Term Outcomes of Community‐Acquired Hepatitis C Infection in a Cohort With Sera Stored From 1971 to 1975 , 2000, Hepatology.

[8]  Campbell K Aitken,et al.  Molecular epidemiology of hepatitis C virus in a social network of injection drug users. , 2004, The Journal of infectious diseases.

[9]  G. Dore,et al.  Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy , 2005, Journal of gastroenterology and hepatology.

[10]  M. Hellard,et al.  Investigation of infection control practices and knowledge of hepatitis C among body-piercing practitioners. , 2003, American journal of infection control.

[11]  B. Denis,et al.  High prevalence of hepatitis C virus infection in Belgian intravenous drug users and potential role of the "cotton-filter" in transmission: the GEMT Study. , 2000, Acta gastro-enterologica Belgica.

[12]  D. Vlahov,et al.  Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. , 1996, American journal of public health.

[13]  S. Storch,et al.  Detection of HCV salivary antibodies by a simple and rapid test. , 2006, Journal of virological methods.

[14]  D. Vlahov,et al.  Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[15]  Rohan Jayasuriya,et al.  Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia. , 2006, Addiction.

[16]  F. Gutzwiller,et al.  HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. , 2001, European journal of public health.

[17]  J. Parry,et al.  Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis , 2005, Journal of viral hepatitis.

[18]  J. Kaldor,et al.  Hepatitis C virus antibody prevalence among injecting drug users at selected needle and syringe programs in Australia, 1995–1997 , 2000 .

[19]  J. Miller,et al.  Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations. , 1998, The New Zealand medical journal.

[20]  S. Vermund,et al.  Network-related mechanisms may help explain long-term HIV-1 seroprevalence levels that remain high but do not approach population-group saturation. , 2000, American journal of epidemiology.

[21]  R. Garfein,et al.  Self-Reported Hepatitis C Virus Antibody Status and Risk Behavior in Young Injectors , 2006, Public health reports.

[22]  A. Ananthakrishnan,et al.  Hepatitis C infection among drug users in northern Thailand. , 2006, The American journal of tropical medicine and hygiene.

[23]  J. Kaldor,et al.  Clearance of hepatitis C virus after newly acquired infection in injection drug users. , 2004, The Journal of infectious diseases.